Drug intelligence / Profile preview

SKY01

Development stage: Preclinical
Lead developer: SEEKYO Therapeutics
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Physical Methods → Gene Addition/Replacement → Gene Therapies, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

SKY01 is a preclinical chemotherapy drug candidate developed by Seekyo for the treatment of solid tumors. It utilizes therapeutic vectors that are specifically activated by enzymes within the tumor microenvironment, offering a potential alternative to Antibody-Drug Conjugates (ADCs). The drug is currently undergoing toxicology and pharmacokinetics studies to prepare for future clinical trials.

Targets

GUSB (Beta-glucuronidase)

Beyond the preview

Go deeper on SKY01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKY01.

Explore the full profile